SCHEDULE: Gryga Trust Discloses 7.7% Stake in Theriva Biologics

The Jeffrey Matthew Gryga Irrevocable Trust and Jeffrey Matthew Gryga have disclosed a beneficial ownership of 7.7% in Theriva Biologics, Inc. common stock.

Summary

• Jeffrey Matthew Gryga Irrevocable Trust and Jeffrey Matthew Gryga have reported beneficial ownership of 739,211 shares of Theriva Biologics, Inc. common stock.
• This represents 7.7% of the company's outstanding common stock.
• The Jeffrey Matthew Gryga Irrevocable Trust holds sole voting and dispositive power over these 739,211 shares.
• Jeffrey Matthew Gryga, as the sole Trustee of the Irrevocable Trust, holds shared voting and dispositive power over the same 739,211 shares.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Theriva Biologics, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant beneficial ownership stake (7.7%) by an individual/trust can be viewed as a moderately positive signal of confidence in the company, although the filing itself is a factual disclosure without explicit sentiment.

Positives

• A significant beneficial ownership stake of 7.7% by an individual/trust may signal confidence in Theriva Biologics, Inc.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide specific industry context or analysis. It indicates a significant individual investment in a biopharmaceutical company.

Stakeholder Impact

• Shareholders: The disclosure of a new significant shareholder may influence market perception and potentially provide a level of stability or confidence.

Key Dates

Keywords

Theriva Biologics, TRVA, Beneficial Ownership, Schedule 13G, Equity Stake, Investment, SEC Filing